These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

197 related items for PubMed ID: 19483650

  • 1. Immunizations with IFNgamma secreting tumor cells can eliminate fully established and invasive rat gliomas.
    Janelidze S, Bexell D, Badn W, Darabi A, Smith KE, Fritzell S, Gunnarsson S, Milos P, Bengzon J, Salford LG, Siesjö P, Visse E.
    J Immunother; 2009; 32(6):593-601. PubMed ID: 19483650
    [Abstract] [Full Text] [Related]

  • 2. Cure of established, intracerebral rat gliomas induced by therapeutic immunizations with tumor cells and purified APC or adjuvant IFN-gamma treatment.
    Siesjö P, Visse E, Sjögren HO.
    J Immunother Emphasis Tumor Immunol; 1996 Sep; 19(5):334-45. PubMed ID: 8941873
    [Abstract] [Full Text] [Related]

  • 3. The combination of ionizing radiation and peripheral vaccination produces long-term survival of mice bearing established invasive GL261 gliomas.
    Newcomb EW, Demaria S, Lukyanov Y, Shao Y, Schnee T, Kawashima N, Lan L, Dewyngaert JK, Zagzag D, McBride WH, Formenti SC.
    Clin Cancer Res; 2006 Aug 01; 12(15):4730-7. PubMed ID: 16899624
    [Abstract] [Full Text] [Related]

  • 4. The human leukemic T-cell line, TALL-104, is cytotoxic to human malignant brain tumors and traffics through brain tissue: implications for local adoptive immunotherapy.
    Kruse CA, Visonneau S, Kleinschmidt-DeMasters BK, Gup CJ, Gomez GG, Paul DB, Santoli D.
    Cancer Res; 2000 Oct 15; 60(20):5731-9. PubMed ID: 11059767
    [Abstract] [Full Text] [Related]

  • 5. Interferon-gamma in brain tumor immunotherapy.
    Kane A, Yang I.
    Neurosurg Clin N Am; 2010 Jan 15; 21(1):77-86. PubMed ID: 19944968
    [Abstract] [Full Text] [Related]

  • 6. Impaired capacity for upregulation of MHC class II in tumor-associated microglia.
    Schartner JM, Hagar AR, Van Handel M, Zhang L, Nadkarni N, Badie B.
    Glia; 2005 Sep 15; 51(4):279-85. PubMed ID: 15818597
    [Abstract] [Full Text] [Related]

  • 7. Adoptive immunotherapy of CNS malignancies.
    Plautz GE, Shu S.
    Cancer Chemother Biol Response Modif; 2001 Sep 15; 19():327-38. PubMed ID: 11686021
    [Abstract] [Full Text] [Related]

  • 8. Effects of intracarotid and intravenous infusion of human TNF and LT on established intracerebral rat gliomas.
    Liu SK, Jakowatz JG, Pollack RB, Ceraldi C, Yamamoto R, Dett C, Lopez F, Camacho C, Carson WE, Sentovich SM.
    Lymphokine Cytokine Res; 1991 Jun 15; 10(3):189-94. PubMed ID: 1883913
    [Abstract] [Full Text] [Related]

  • 9. Synergism between GM-CSF and IFNgamma: enhanced immunotherapy in mice with glioma.
    Smith KE, Janelidze S, Visse E, Badn W, Salford L, Siesjö P, Darabi A.
    Int J Cancer; 2007 Jan 01; 120(1):75-80. PubMed ID: 17044023
    [Abstract] [Full Text] [Related]

  • 10. Efficacy of systemic radionuclide therapy with p-131I-iodo-L-phenylalanine combined with external beam photon irradiation in treating malignant gliomas.
    Samnick S, Romeike BF, Lehmann T, Israel I, Rübe C, Mautes A, Reiners C, Kirsch CM.
    J Nucl Med; 2009 Dec 01; 50(12):2025-32. PubMed ID: 19910430
    [Abstract] [Full Text] [Related]

  • 11. Autologous natural killer cell therapy for human recurrent malignant glioma.
    Ishikawa E, Tsuboi K, Saijo K, Harada H, Takano S, Nose T, Ohno T.
    Anticancer Res; 2004 Dec 01; 24(3b):1861-71. PubMed ID: 15274367
    [Abstract] [Full Text] [Related]

  • 12. Dual-targeted antitumor effects against brainstem glioma by intravenous delivery of tumor necrosis factor-related, apoptosis-inducing, ligand-engineered human mesenchymal stem cells.
    Yang B, Wu X, Mao Y, Bao W, Gao L, Zhou P, Xie R, Zhou L, Zhu J.
    Neurosurgery; 2009 Sep 01; 65(3):610-24; discussion 624. PubMed ID: 19687708
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Cure of established GL261 mouse gliomas after combined immunotherapy with GM-CSF and IFNgamma is mediated by both CD8+ and CD4+ T-cells.
    Smith KE, Fritzell S, Badn W, Eberstål S, Janelidze S, Visse E, Darabi A, Siesjö P.
    Int J Cancer; 2009 Feb 01; 124(3):630-7. PubMed ID: 18972433
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. IGF-I triple helix gene therapy of rat and human gliomas.
    Trojan LA, Kopinski P, Mazurek A, Chyczewski L, Ly A, Jarocki P, Nikliński J, Shevelev A, Trzos R, Pan Y, Gitis DJ, Bierwagen M, Czapiewska JL, Wei MX, Michalkiewicz J, Henin D, Popiela T, Evrard F, Kasprzak H, Anthony D, Trojan J.
    Rocz Akad Med Bialymst; 2003 Feb 01; 48():18-27. PubMed ID: 14737936
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Intracerebral interleukin 12 induces glioma rejection in the brain predominantly by CD8+ T cells and independently of interferon-gamma.
    Vetter M, Hofer MJ, Roth E, Pircher HP, Pagenstecher A.
    J Neuropathol Exp Neurol; 2009 May 01; 68(5):525-34. PubMed ID: 19525900
    [Abstract] [Full Text] [Related]

  • 19. Immunogene therapy as a treatment for malignant brain tumors in young mice.
    Glick RP, Lichtor T, Lin H, Tarlock K, Cohen EP.
    J Neurosurg; 2006 Jul 01; 105(1 Suppl):65-70. PubMed ID: 16871873
    [Abstract] [Full Text] [Related]

  • 20. Antitumor vaccination of patients with glioblastoma multiforme: a pilot study to assess feasibility, safety, and clinical benefit.
    Steiner HH, Bonsanto MM, Beckhove P, Brysch M, Geletneky K, Ahmadi R, Schuele-Freyer R, Kremer P, Ranaie G, Matejic D, Bauer H, Kiessling M, Kunze S, Schirrmacher V, Herold-Mende C.
    J Clin Oncol; 2004 Nov 01; 22(21):4272-81. PubMed ID: 15452186
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.